Compare Adaptive Biotechnologies Corp (ADPT) vs Rex Fang & Innovation Equity Premium Income ETF (FEPI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Rex Fang & Innovation Equity Premium Income ETF — how do they compare? Adaptive Biotechnologies Corp trades at $20.24 (market cap $3.33B), while Rex Fang & Innovation Equity Premium Income ETF trades at $41.7. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, Rex Fang & Innovation Equity Premium Income ETF nearer its low. Which is the better fit depends on your goals.
| ADPT | FEPI | |
|---|---|---|
Market Cap | $3.33B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $22.37 | $49.54 |
52-Week Low | $10.24 | $38.13 |
Enterprise Value | $3.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
FEPI (REX FANG & Innovation Equity Premium Income ETF) trades at $42.53, up 1.5% with a bearish technical signal. The ETF employs a covered call strategy on concentrated tech holdings, generating high weekly dividends but facing NAV erosion concerns. Recent transition to weekly distributions aims to enhance income appeal, though technical indicators show selling pressure outweighing buying signals.
The outlook balances high yield appeal against structural limitations. The 25% dividend yield attracts income seekers, but the covered call strategy caps upside potential during tech rallies. Key risks include concentrated exposure to volatile AI/mega-cap stocks and persistent NAV erosion, requiring careful risk-reward assessment for long-term holders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Rex Fang & Innovation Equity Premium Income ETF
FEPI provides exposure to top innovation stocks while generating monthly income. It uses a covered call strategy on high-volatility tech stocks to capture option premiums for investors.
Read more on FEPI →
